Beyondspring Inc (NASDAQ:BYSI) has been given an average recommendation of “Buy” by the six analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $35.00.
BYSI has been the topic of several research analyst reports. ValuEngine upgraded Beyondspring from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 target price (up from $30.00) on shares of Beyondspring in a report on Monday, June 15th. Finally, Zacks Investment Research downgraded shares of Beyondspring from a “hold” rating to a “sell” rating in a report on Monday, July 20th.
Several large investors have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Beyondspring by 3.0% during the 1st quarter. BlackRock Inc. now owns 689,277 shares of the company’s stock worth $8,830,000 after acquiring an additional 19,930 shares in the last quarter. State Street Corp lifted its holdings in shares of Beyondspring by 4.6% during the first quarter. State Street Corp now owns 206,339 shares of the company’s stock valued at $2,643,000 after purchasing an additional 9,134 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Beyondspring during the fourth quarter valued at $1,477,000. Geode Capital Management LLC boosted its position in shares of Beyondspring by 13.8% in the 1st quarter. Geode Capital Management LLC now owns 93,721 shares of the company’s stock valued at $1,200,000 after purchasing an additional 11,388 shares during the period. Finally, Russell Investments Group Ltd. purchased a new position in Beyondspring in the 1st quarter worth about $471,000. Institutional investors own 6.60% of the company’s stock.
BYSI stock opened at $11.03 on Tuesday. The firm’s 50-day moving average is $14.76 and its two-hundred day moving average is $15.07. Beyondspring has a 52 week low of $9.38 and a 52 week high of $23.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.44 and a current ratio of 2.44.
Beyondspring (NASDAQ:BYSI) last posted its quarterly earnings data on Thursday, June 11th. The company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.08). Equities analysts anticipate that Beyondspring will post -2.45 earnings per share for the current fiscal year.
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
See Also: Why Invest in Dividend Kings
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.